Where in-house PGx programs get stuck

Most labs already run the wet-lab side well. The stall happens downstream: variant call files, CSV exports, and MassARRAY or array output have to be reconciled against clinical evidence, formatted into branded reports, and reviewed before release. Built by hand, that pipeline is fragile and slow to scale.

A white-label platform moves interpretation into evidence-graded workflows. Instead of asking staff to chase down the latest guidance for every gene-drug pair, the platform grades each genotype against curated sources automatically and routes it for sign-out. The result is not just speed, but reports that are consistent and defensible.

Blocker: reconciling the evidence

The hardest part of a PGx report is not the genotype — it is deciding what it means. Guidance is scattered across CPIC, FDA biomarker labeling, DailyMed, DPWG, and PharmGKB, and the sources do not always agree. Reconciling them by hand for every gene and drug is slow and hard to keep defensible.

A platform that has already curated that evidence makes each interpretation:

• graded

• sourced

• auditable

SignalPGx grades 50 pharmacogenes and about 950 medications against 15+ curated sources, so the lab starts from reconciled evidence instead of building it.

Blocker: keeping guidelines current

PGx evidence is a moving target. CPIC updates recommendations, the FDA revises labeling, and a patient's medication list changes over time. A report that was accurate at sign-out can quietly go out of date, and manually re-checking a back catalog of reports is not realistic.

This is where Living Reports matter. SignalPGx re-analyzes prior reports automatically when guidelines or a patient's medications change, and flags the ones that moved for a fresh medical-director review. The archive stays current without a lab combing through it by hand.

Blocker: report software and delivery

Even with the science handled, the report still has to look like the lab's own and land where clinicians work. Building branded templates, wiring up delivery into the EHR, and supporting different ordering systems is a software project in itself — one most labs do not want to own.

A white-label platform absorbs that work. Reports carry the lab's branding, and delivery runs over FHIR R4, HL7 ORU, CDS Hooks, and SMART on FHIR. A Patient Passport — a revocable QR link to a minimal-PHI view — lets patients carry their results, with the lab able to revoke access at any time.

Blocker: medical review and sign-out

Every clinical PGx report needs a qualified reviewer, and review time is often the real bottleneck. Scale the volume and the medical director becomes the constraint, especially when each report has to be assembled from raw evidence before anyone can even read it.

SignalAI assists the review — it never replaces it.

SignalAI surfaces and flags gene-drug interactions so the reviewer starts from a structured draft, but every report is reviewed and signed out by the lab's medical director. Clinicians stay in control, and final prescribing decisions always remain with the ordering physician.

decision = model.predict(input_data)
execute(decision)

How a white-label platform gets you live in days

Put those pieces together and the reason programs stall becomes clear: each blocker is a project on its own, and doing all of them in-house takes months. A platform that already solves them turns launch into configuration rather than construction.

Most labs go live in 5-7 days, with the platform handling:

1. evidence-graded interpretation

2. branded reports and EHR delivery

3. medical-director review and updates

Because the platform is multi-tenant and configured per lab, onboarding is setup and branding rather than a build. The lab keeps running its own genotyping and CLIA workflows; SignalPGx supplies the reporting layer on top.

Conclusion

A white-label platform does not replace the lab — it removes what was slowing the launch.

It is built on secured AWS with encryption in transit and at rest, RBAC, strict tenant isolation, and a full audit trail, and it is HIPAA- and GDPR-compliant. With transparent per-report pricing and a pilot available, a lab can move from stalled to live without building the pipeline itself.